Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MERCK, LILLY, MARION LEAD DRUG STOCKS TO BIGGEST GAIN IN NEARLY TWO YEARS

Executive Summary

MERCK, LILLY, MARION LEAD DRUG STOCKS TO BIGGEST GAIN IN NEARLY TWO YEARS Merck (up 6 to 88-1/2), Lilly (up 4-1/2 to 59), and Marion (up 4-3/8 to 39-1/2) led rebounding Pharmaceutical stocks on the "F-D-C" Index to the group's biggest single week gain in almost two years. Overall, 52 of 53 stocks listed on the index advanced -- Cooper fell 7/8 to 21-7/8 -- as the Composite posted its largest single week jump since the August 1982 rally, climbing 7.4% compared with the Dow's 7.8% leap. Other drug stocks leading the charge were SmithKline Beckman (up 4-1/4 to 58-7/8), Abbott (up 2-7/8 to 46-1/4), and Squibb (up 2-7/8 to 47-7/8). Novo (up 6 to 46-3/8) and Pfizer (up 3-1/4 to 35-1/2) were among the Diversified leaders, while Walgreens (up 5-5/8 to 40-1/2) was top for the Chains. Chart omitted.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS006994

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel